Axi­tinib CAS 319460-85-0

Iden­ti­fi­ca­tion Prop­er­ties Safe­ty Data Spec­i­fi­ca­tions & Oth­er Information Links

Iden­ti­fi­ca­tion

CAS Number

319460-85-0

Name

Axi­tinib

Key inter­me­di­ates of the Axi­tinib CAS:886230-77-9;Name:(E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole CAS:885126-35-2;Name:N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl]thio]benzamide CAS:86230-76-8 CAS:20054-45-9;Name:N-methyl-2-sulfanylbenzamide

Syn­onyms

319460-85-0 [RN] 8720 axi­tinib [Span­ish] [INN] axi­tinib [French] [INN] Axi­tinib [INN] [USAN] [Wiki] axi­tinibum [Latin] [INN] Ben­za­mide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- Ben­za­mide, N-methyl-2-[[3-[(E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- [ACD/​Index Name] C9LVQ0YUXG N-Methyl-2-({3-[(E)-2-(2-pyridinyl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamid [Ger­man] [ACD/IUPAC Name] N-Methyl-2-({3-[(E)-2-(2-pyridinyl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide [ACD/IUPAC Name] N-Méthyl-2-({3-[(E)-2-(2-pyridinyl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide [French] [ACD/IUPAC Name] N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide N-Methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide UNII-C9LVQ0YUXG акситиниб [Russ­ian] [INN] أكسيتينيب [Ara­bic] [INN] 阿昔替尼 [Chi­nese] [INN] (E)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide (E)-N-methyl-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamide (trans-4-Methylpyrrolidin-3-yl)methanol [319460-85-0] {2-[3-((1E)-2-(2-pyridyl)vinyl)(1H-indazol-6-ylthio)]phenyl}-N-methylcarboxamide 319463-51-9 [RN] 70356-09-1 [RN] 945723-36-4 [RN] AG 013736|AG-013736|AG013736|Inly­ta® AG013736 AG-013736 ; AG 013736 ; AG013736 AG13736 Avoben­zone [INN] [USAN] [USP] [Wiki] AXI Axi­tinib (AG 013736) Axi­tinib [USAN] axi­tinibum Axtin­tib Ben­za­mide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)- Inly­ta Inly­ta® MFCD09837898 [MDL num­ber] MFCD14708210 N-Methyl-[[3[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-i ndazol-6-yl)sulfanyl)benzamide N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide N-methyl-2-[[3-[(E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide N-methyl-2-[[3-[(E)-2-(2-pyridyl)vinyl]-1H-indazol-6-yl]sulfanyl]benzamide N-methyl-2-[[3-[(E)-2-(2-pyridyl)vinyl]-1H-indazol-6-yl]thio]benzamide N-Methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide N-methyl-2-[[3-[(Z)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide N-Methyl-2-[3-(2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide N-methyl-2-3-(1E)-2-(2-pyridinyl)ethenyl-1H-indazol-6-ylthio-benzamide S1005 UNII :C9LVQ0YUXG

Mol­e­c­u­lar Structure

SMILES

CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4

Std­InChI

InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+

Std­InChIKey

RITAVMQDG­B­JQJZ-FMIVXF­B­M­SA-N

Mol­e­c­u­lar Formula

C22H18N4OS

Mol­e­c­u­lar Weight

386.47

MDL Number

MFCD09837898

Appear­ance

Pale yel­low pow­der or off-white pow­der

Safe­ty Data

Sym­bol

HS07, GHS09

Sig­nal Word

Warn­ing

Haz­ard Statements

H302-H400

Pre­cau­tion­ary Statements

P273

RIDADR

UN 3077 9 / PGI­II

WGK Germany

3 

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Axi­tinib CAS 319460-85-0

Stan­dard

Enter­prise stan­dard

Iden­ti­fi­ca­tion Methods

HNMR,HPLC

Puri­ty

99%min

Loss on Drying

≤1.0%

Residue on Ignition

≤ 1.0%

Sin­gle max Impurity

≤ 0.3%

Total Impu­ri­ties

≤ 1.0%

Pack­age

Accord­ing to cus­tomer require­ments to pack­ag­ing

Stor­age

Under the room tem­per­a­ture and away from light

Appli­ca­tion

Com­mon­ly used for the treat­ment of kid­ney can­cer.

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Ltd(http://​www​.cam​ing​.com/), and here is the cor­re­spond­ing linkhttp://​www​.cam​ing​.com/​a​x​i​t​i​n​i​b​-​c​a​s​-​3​1​9​4​6​0​-​8​5​-0/

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you short­ly (Please change screen to hor­i­zon­tal for com­plete brows­ing if you are check­ing Wat­son on your mobile phone).